This inventor holds 204 USPTO granted patents and 56 published patent applications, plus 38 CIPO patents and 42 EPO patents, primarily in Monoclonal Antibodies (CPC class A01K2227-105). Top assignees: Regeneron Pharmaceuticals, Inc., Institute for Research in Biomedicine, Yale University. Active years: 1992-2026.
Inventors with similar research interests:
Location History:
- Tarrytown, US (1994)
- Briarcliff Manor, NY (US) (1992 - 2001)
- Elmhurst, NY (US) (1997 - 2001)
- New York, NY (US) (1993 - 2005)
- Tarrytown, NY (US) (2020)
- Yorktown Heights, NY (US) (1995 - 2024)
Company Filing History:
194 out of 1,479 
20 out of 76 
20 out of 1,365 
Years Active: 1992-2026
Areas of Expertise:
Title: George D Yancopoulos: Pioneering Biotechnologist with an Impressive Patent Portfolio
Introduction:
Throughout his exceptional career, George D Yancopoulos has made significant contributions to the field of biotechnology, particularly in the development of innovative therapies and treatments for various diseases. This article will explore Yancopoulos' latest patents, career highlights, notable collaborations, and his overall impact on the field.
Latest Patents:
Yancopoulos has an impressive patent portfolio, with a total of 176 patents to his name. Among his notable recent patents are the following:
1. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments:
This patent focuses on antibodies and antigen-binding fragments specifically designed to bind to the spike protein found in coronaviruses. These antibodies hold potential in treating and preventing viral infections, including coronavirus infections such as COVID-19.
2. Methods and compositions for targeted genetic modification using paired guide RNAs:
This patent presents methods and compositions for precise genetic modifications within the genome of cells. By utilizing Cas proteins and multiple guide RNAs targeting specific locations, Yancopoulos aims to create biallelic targeted modifications and homozygous alleles. This breakthrough approach opens doors for advancing genetic research and animal models with modified genomes.
Career Highlights:
Yancopoulos has had a remarkable career marked by notable accomplishments. He has worked with renowned organizations such as Regeneron Pharmaceuticals, Inc. and Yale University. Some of his career highlights include:
1. Co-founding Regeneron Pharmaceuticals, Inc.:
Yancopoulos played a pivotal role in establishing Regeneron Pharmaceuticals, a leading biotechnology company known for its groundbreaking drug discoveries, including the monoclonal antibody therapy used to treat various diseases.
2. Research and Development Leadership:
As Regeneron's President and Chief Scientific Officer, Yancopoulos spearheaded the company's advanced research and development efforts, resulting in the introduction of numerous life-changing therapies. His vision and leadership enhanced the company's reputation as an industry frontrunner.
Collaborations:
George D Yancopoulos has collaborated with esteemed professionals to realize groundbreaking innovations. Notable collaborations include working with:
1. Andrew J Murphy:
Yancopoulos collaborated with Andrew J Murphy, a renowned scientist recognized for his research in immunology and infectious diseases. Together, they have made significant contributions to the field of biotechnology, particularly in the development of targeted therapies.
2. David M Valenzuela:
Another important collaboration for Yancopoulos is with David M Valenzuela, a respected expert in molecular biology. Their joint efforts have led to novel advancements in genetic modification techniques, which have revolutionized the field of biotechnology.
Conclusion:
George D Yancopoulos has established himself as a leading figure in biotechnology, with an impressive patent portfolio and numerous contributions to the development of innovative therapies. His recent patents for anti-SARS-CoV-2 antibodies and targeted genetic modifications showcase his commitment to addressing global health challenges and advancing the field. Collaborations with experts such as Andrew J Murphy and David M Valenzuela further underscore Yancopoulos' collaborative spirit and dedication to pioneering research. Through his remarkable career, Yancopoulos has left an indelible mark on the field of biotechnology and continues to drive progress towards improved treatments and medical breakthroughs.